|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM273201077 |
| 003 |
DE-627 |
| 005 |
20250221205417.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2017.06.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0910.xml
|
| 035 |
|
|
|a (DE-627)NLM273201077
|
| 035 |
|
|
|a (NLM)28642148
|
| 035 |
|
|
|a (PII)S1521-6616(17)30107-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Spadaro, Michela
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.08.2017
|
| 500 |
|
|
|a Date Revised 03.01.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2017. Published by Elsevier Inc.
|
| 520 |
|
|
|a Glatiramer acetate (GA) is a widely used treatment for multiple sclerosis (MS), with incompletely defined mechanism of action. Short-term studies suggested its involvement in the modulation of anti-inflammatory cytokines and regulatory T cells (Treg), while long-term effect is still unknown. To investigate this aspect, we analyzed by flow-cytometry peripheral-blood Treg, natural killer (NK), CD4 and CD8 T-cells and anti-inflammatory CD14+CD163+ monocytes from 37 healthy donor and 90 RRMS patients divided in untreated, treated with GA for 12months and from 34 to 192months. While NK, CD4 and CD8 T-cells did not show any significant differences among groups over time, we demonstrated that GA increased the anti-inflammatory monocytes and restored the Treg level in both GA-treated groups. Both these effects are a characteristic of responder patients and are observed not just in short-term but even after as long as a decade of GA treatment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Glatiramer acetate
|
| 650 |
|
4 |
|a M2 monocytes
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Treg
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Differentiation, Myelomonocytic
|2 NLM
|
| 650 |
|
7 |
|a CD163 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Lipopolysaccharide Receptors
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Cell Surface
|2 NLM
|
| 650 |
|
7 |
|a Glatiramer Acetate
|2 NLM
|
| 650 |
|
7 |
|a 5M691HL4BO
|2 NLM
|
| 700 |
1 |
|
|a Montarolo, Francesca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Perga, Simona
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martire, Serena
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brescia, Federica
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Malucchi, Simona
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bertolotto, Antonio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 181(2017) vom: 26. Aug., Seite 83-88
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:181
|g year:2017
|g day:26
|g month:08
|g pages:83-88
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2017.06.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 181
|j 2017
|b 26
|c 08
|h 83-88
|